We maintain our Buy rating on Aurobindo Pharma (APL) and revise TP to Rs1,270 (earlier Rs1,010) based on 18x March'20E EPS of Rs70.4. APL has agreed to acquire the dermatology and oral solid business of Sandoz-a division of...